Catalio Capital Management, LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Catalio Capital Management, LP disclosed 38 US equity positions worth $540.9m in its Q3 2025 13F filing. The largest position was LLY at 8.1% of the reported book, followed by ABBV and BBIO. Against the Q2 2025 filing, it opened 10 new positions, added to 10 and reduced 13 among the top 38 holdings.
What did Catalio Capital Management, LP own in Q3 2025? Top 38 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | LLY ELI LILLY & CO | Healthcare | 8.1% | $43.8m | 57,376 | 6% | added |
| 2 | ABBV ABBVIE INC | Healthcare | 6.6% | $35.9m | 154,834 | – | new |
| 3 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 6.0% | $32.3m | 622,729 | -33% | reduced |
| 4 | ISRG INTUITIVE SURGICAL INC | Healthcare | 5.9% | $31.9m | 71,343 | 26% | added |
| 5 | ASND ASCENDIS PHARMA A/S | Healthcare | 5.3% | $28.8m | 144,954 | -19% | reduced |
| 6 | SLNOEUR SOLENO THERAPEUTICS INC | 5.2% | $28.3m | 418,245 | 2% | added | |
| 7 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.9% | $26.3m | 667,615 | -11% | reduced |
| 8 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.7% | $25.7m | 262,972 | 15% | added |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 4.6% | $24.8m | 1,614,717 | -23% | reduced |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 4.6% | $24.8m | 451,581 | -25% | reduced |
| 11 | NTRA NATERA INC | Healthcare | 4.4% | $23.9m | 148,369 | 52% | added |
| 12 | REGN REGENERON PHARMACEUTICALS | Healthcare | 3.7% | $19.9m | 35,344 | – | new |
| 13 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.4% | $18.3m | 651,810 | -3% | reduced |
| 14 | QURE UNIQURE NV | 3.1% | $16.5m | 282,940 | -32% | reduced | |
| 15 | IRON DISC MEDICINE INC | Healthcare | 2.6% | $14.3m | 216,527 | 606% | added |
| 16 | ABVX ABIVAX SA | 2.5% | $13.8m | 162,141 | – | new | |
| 17 | SUPN SUPERNUS PHARMACEUTICALS INC | Healthcare | 2.5% | $13.7m | 287,090 | – | new |
| 18 | EXK EXACT SCIENCES CORP | Basic Materials | 2.5% | $13.6m | 248,987 | – | new |
| 19 | PHAT PHATHOM PHARMACEUTICALS INC | 2.5% | $13.3m | 1,128,521 | 68% | added | |
| 20 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 2.4% | $13.2m | 884,890 | -37% | reduced |
| 21 | RNAGBP AVIDITY BIOSCIENCES INC | 2.1% | $11.5m | 263,256 | – | new | |
| 22 | ADMA ADMA BIOLOGICS INC | Healthcare | 1.9% | $10.0m | 684,508 | 20% | added |
| 23 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.6% | $8.8m | 291,262 | 36% | added |
| 24 | GUTS FRACTYL HEALTH INC | 1.5% | $8.3m | 5,214,236 | 2334% | added | |
| 25 | GRAL GRAIL INC | 1.5% | $8.2m | 137,928 | – | new | |
| 26 | TARA PROTARA THERAPEUTICS INC | 1.2% | $6.5m | 1,500,793 | -8% | reduced | |
| 27 | SEPN SEPTERNA INC | 1.0% | $5.5m | 294,360 | 0% | held | |
| 28 | CDTX CIDARA THERAPEUTICS INC | 0.9% | $5.1m | 53,333 | – | new | |
| 29 | KYTX KYVERNA THERAPEUTICS INC | 0.7% | $3.5m | 586,909 | 0% | held | |
| 30 | ELDN ELEDON PHARMACEUTICALS INC | 0.5% | $2.7m | 1,061,132 | – | new | |
| 31 | OM OUTSET MED INC | 0.3% | $1.7m | 118,279 | -29% | reduced | |
| 32 | MGX METAGENOMI INC | 0.2% | $1.3m | 528,993 | 0% | held | |
| 33 | ATAI LIFE SCIENCES NV | 0.2% | $1.0m | 196,858 | 0% | held | |
| 34 | HYPR HYPERFINE INC | 0.2% | $992.6k | 684,541 | -10% | reduced | |
| 35 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.2% | $954.5k | 133,131 | -18% | reduced |
| 36 | KPTI KARYOPHARM THERAPEUTICS INC | 0.2% | $935.1k | 142,984 | -2% | reduced | |
| 37 | PVLA PALVELLA THERAPEUTICS INC NE | 0.1% | $752.9k | 12,010 | – | new | |
| 38 | FTH SENSEI BIOTHERAPEUTICS INC | 0.0% | $139.1k | 14,718 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.